论文部分内容阅读
目的观察重组组织型纤溶酶原激活剂静脉溶栓治疗高龄急性脑梗死的疗效及安全性。方法选取医院收治的高龄急性脑梗死患者87例,发病时间<5 h,随机分为对照组43例,观察组44例。对照组予以常规抗血小板治疗,观察组予以重组组织型纤溶酶原激活剂静脉溶栓治疗,观察比较2组临床疗效、日常生活能力(Barthel指数)评分及不良反应发生率。结果治疗后,观察组总有效率为93.18%,显著高于对照组的69.77%(P<0.01);治疗7 d、14 d及1个月观察组Barthel评分均明显高于对照组(P<0.01);2组不良反应发生率比较,差异无统计学意义(P>0.05)。结论重组组织型纤溶酶原激活剂静脉溶栓治疗高龄急性脑梗死,疗效显著,可有效改善患者日常生活能力,且安全性高。
Objective To observe the efficacy and safety of recombinant tissue plasminogen activator intravenous thrombolysis in the treatment of elderly acute cerebral infarction. Methods Totally 87 elderly patients with acute cerebral infarction admitted to hospital were enrolled in this study. The onset time was less than 5 h. They were randomly divided into control group (n = 43) and observation group (n = 44). The control group was given routine antiplatelet therapy, and the observation group was given recombinant tissue plasminogen activator intravenous thrombolysis. The clinical curative effect, Barthel index score and incidence of adverse reactions in the two groups were observed and compared. Results After treatment, the total effective rate in the observation group was 93.18%, significantly higher than that in the control group (69.77%, P <0.01). The Barthel scores in the observation group at 7 d, 14 d and 1 month after treatment were significantly higher than those in the control group (P < 0.01). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion Recombinant tissue plasminogen activator intravenous thrombolysis in the treatment of elderly patients with acute cerebral infarction, significant effect, which can effectively improve the daily living ability of patients with high safety.